Benfotiamine "little better than snake oil"

29 June 2008

A popular vitamin supplement is being advertised with claims that are demonstrably untrue, as revealed by research published in the open access, pier-reviewed journal BMC Pharmacology.

The product, benfotiamine is a synthetic derivative of thiamine (vitamin B1). It is marketed heavily as a dietary supplement using a selection of unsubstantiated, "not-quite-medical" claims that tend to characterize this field. A large part of this campaign has been built around the belief that benfotiamine is lipid-soluble and, therefore, more physiologically active. Scientific research led by Lucien Bettendorff of the Center for Cellular and Molecular Neurobiology at the University of Liege in Belgium has entirely disproved these claims.

A severe deficiency of thiamine is known to cause weight loss, emotional disturbances, impaired sensory perception, weakness and pain in the limbs, and periods of irregular heart rate. Deficiencies can occur as a result of alcoholism or malnutrition. As thiamine itself is very poorly absorbed by the body, it must be taken in as various precursor forms. This research shows that benfotiamine may not be as effective in this regard as has been claimed, in particular concerning its ability to raise effective thiamine levels in the central nervous system.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight